FILE - This April 28, 2010, file photo shows the GlaxoSmithKline offices in London. On Friday, July 20, 2018, the U.S. Food and Drug Administration approved GlaxoSmithKline’s Krintafel, a simpler, one-dose treatment, to prevent relapses of malaria. (AP Photo/Kirsty Wigglesworth, File)
July 20, 2018 - 4:58 pm
U.S. regulators have approved a simpler, one-dose treatment to prevent relapses of malaria. Standard treatment takes two weeks and many patients don't finish taking all the doses. Malaria is caused by parasites that are spread through mosquito bites. The parasites can remain dormant in the liver...
Read More